181 related articles for article (PubMed ID: 20486463)
1. Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis.
Brouda I; Edison B; Van Cott A; Green BA
Cutis; 2010 Apr; 85(4):214-20. PubMed ID: 20486463
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis.
Alora-Palli MB; Brouda I; Green B; Kimball AB
Arch Dermatol; 2010 Aug; 146(8):919-22. PubMed ID: 20713833
[No Abstract] [Full Text] [Related]
4. Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis.
Singh P; Gupta S; Abidi A; Krishna A
J Drugs Dermatol; 2013 Aug; 12(8):868-73. PubMed ID: 23986159
[TBL] [Abstract][Full Text] [Related]
5. Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis.
Tzaneva S; Hönigsmann H; Tanew A
Br J Dermatol; 2003 Aug; 149(2):350-3. PubMed ID: 12932242
[TBL] [Abstract][Full Text] [Related]
6. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis.
Sharma V; Kaur I; Kumar B
Int J Dermatol; 2003 Oct; 42(10):834-8. PubMed ID: 14521705
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis.
Pinheiro N
Br J Clin Pract; 1997; 51(1):16-9. PubMed ID: 9158266
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand.
Thawornchaisit P; Harncharoen K
J Med Assoc Thai; 2007 Oct; 90(10):1997-2002. PubMed ID: 18041415
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
Feldman SR; Mills M; Brundage T; Eastman WJ
J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
[TBL] [Abstract][Full Text] [Related]
11. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone.
Bagel J
J Drugs Dermatol; 2009 Apr; 8(4):351-7. PubMed ID: 19363853
[TBL] [Abstract][Full Text] [Related]
12. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
Tirado-Sánchez A; Ponce-Olivera RM
Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
[TBL] [Abstract][Full Text] [Related]
13. Management of psoriasis with calcipotriol used as monotherapy.
Ramsay CA
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S53-4. PubMed ID: 9344185
[TBL] [Abstract][Full Text] [Related]
14. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis.
Tham SN; Lun KC; Cheong WK
Br J Dermatol; 1994 Nov; 131(5):673-7. PubMed ID: 7999599
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL
Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
[TBL] [Abstract][Full Text] [Related]
17. Comparison of calcipotriene (Dovonex) with a coal tar emulsion (Exorex) in treating psoriasis in adults: a pilot study.
Veronikis IE; Malabanan AO; Holick MF
Arch Dermatol; 1999 Apr; 135(4):474-5. PubMed ID: 10206065
[No Abstract] [Full Text] [Related]
18. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
Highton A; Quell J
J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
[TBL] [Abstract][Full Text] [Related]
19. A novel LCD (coal tar) solution for psoriasis does not discolor naturally light or color-processed hair in an exaggerated exposure test model.
Johnson C; Edison B; Brouda I; Green B
J Cosmet Dermatol; 2009 Sep; 8(3):211-5. PubMed ID: 19735520
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.
Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
